



## **Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference**

January 8, 2020

WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 8, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the 38<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, January 15, 2020 at 11:30 a.m. PT (2:30 p.m. ET).

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors & Media" section on the Kala website at <http://kalarx.com>.

### **About Kala Pharmaceuticals, Inc.**

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200108005005/en/>

Source: Kala Pharmaceuticals, Inc.

### **Investors:**

Hannah Deresiewicz

[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

212-362-1200